Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29343351 | 0.89 | CARM1 (0.44) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL21673652 | 0.84 | HRH3 (0.45) | SIGMAR1KDM4ERECQLTDP1HRH3 | |
| SCHEMBL12704907 | 0.83 | SIGMAR1 (0.54) | CARM1PRMT6PRMT1PRMT8ALDH1A1 | |
| SCHEMBL20372865 | 0.83 | KDM4E (0.44) | SIGMAR1KDM4ERECQLTDP1HRH3 | |
| SCHEMBL29325463 | 0.83 | POLB (0.41) | POLBKDM4EHRH3KMT2A | |
| SCHEMBL1307798 | 0.83 | GNAO1 (0.43) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL29330279 | 0.82 | POLB (0.39) | POLBHRH3KMT2A | |
| SCHEMBL20234909 | 0.82 | KDM4E (0.55) | ALDH1A1SIGMAR1KDM4ERECQLTDP1 | |
| SCHEMBL21025920 | 0.81 | CARM1 (0.54) | CARM1PRMT6PRMT1PRMT8POLB | |
| SCHEMBL20234910 | 0.80 | HRH3 (0.56) | ALDH1A1SIGMAR1KDM4ERECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238423-A9 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | BCL2A1, BCL2L1, BCL3 | CARM1 2895/4885PRMT6 4589/4885PRMT1 3753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.